Galderma Group AG (XSWX:GALD) Current Deferred Revenue: CHF0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GALD Galderma Group AG XSWX:GALD
14 GF Score
Price CHF169.90
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG Current Deferred Revenue?

Galderma Group AG XSWX:GALD +1.98% 14 Current Deferred Revenue is CHF0 Mil as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Galderma Group AG's current deferred revenue for the quarter that ended in Dec. 2025 was CHF0 Mil.

Galderma Group AG Current Deferred Revenue Related Terms

Galderma Group AG Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Current Deferred Revenue Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
0.00 0.00 0.00 0.00 0.00

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
XSWX:GALD
14GF Score
Galderma Group AG XSWX:GALD
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of CHF0 Mil mean?
Galderma Group AG (XSWX:GALD) has a Current Deferred Revenue of CHF0 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Galderma Group AG and its competitors.
Is Galderma Group AG's Current Deferred Revenue too high?
Galderma Group AG's current Current Deferred Revenue is CHF0 Mil. Overall, Galderma Group AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Current Deferred Revenue compare to ZTS and UTHR?
Galderma Group AG's Current Deferred Revenue of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Current Deferred Revenue is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Current Deferred Revenue of CHF0 Mil. The current Current Deferred Revenue is CHF0 Mil. Galderma Group AG's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Current Deferred Revenue is CHF0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
14GF Score

Get the complete analysis for XSWX:GALD

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF169.90
Price